Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers

Clinical and Translational Science(2020)10.1111/cts.12810Source: DataRank Database

Twice‐Daily Doravirine Overcomes the Interaction Effect from Once‐Weekly Rifapentine and Isoniazid in Healthy Volunteers is a research paper published in Clinical and Translational Science (2020). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.10)OA: goldTopics (89)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Joseph Schaefer ORCID,Richard Zheng ORCID,Tingting Zhan ORCID,Walter K. Kraft ORCID,Edwin Lam ORCID

Live enrichment

PubMed:32407548 PMC:PMC7719366 OpenAlex:https://openalex.org/W3025020234

National Institutes of Health

Grant: T32GM008562

National Institutes of Health

Grant: 5T32GM008562-12

Clinical Pharmacology Training Program

FWCI

0.10

Citation Percentile

0.5%

Citation Trend

2021

2022

2023

2025

goldLicense: cc-by-nd

journalhttps://ascpt.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.12810

publisherhttps://ascpt.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.12810

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fcts.12810

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12810

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1111/cts.12810

Fields of Study

HIV/AIDS drug development and treatmentTuberculosis Research and EpidemiologyPneumocystis jirovecii pneumonia detection and treatment0301 basic medicine03 medical and health sciences0303 health sciencesAdolescentAdultAntitubercular AgentsArea Under CurveDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHealthy VolunteersHumansIsoniazidMaleMiddle AgedProspective StudiesPyridonesReverse Transcriptase InhibitorsRifampinTriazolesTuberculosisYoung Adult

MeSH Terms

AdolescentAdultAntitubercular AgentsDrug Administration ScheduleDrug InteractionsFemaleHumansIsoniazidMaleMiddle AgedProspective StudiesPyridonesRifampinTriazolesTuberculosisHIV InfectionsReverse Transcriptase InhibitorsArea Under CurveYoung AdultHealthy Volunteers

Keywords

RifapentineMedicinePharmacokineticsIsoniazidRifamycinConfidence intervalPharmacologyReverse-transcriptase inhibitorDrug interactionHuman immunodeficiency virus (HIV)Internal medicineViral loadAntibioticsTuberculosisImmunologyChemistryAntiretroviral therapyAdultMaleAdolescentPyridonesAntitubercular Agents610HIV InfectionsDrug Administration ScheduleYoung AdultdoravirineMedicine and Health Sciences617HumansDrug InteractionsProspective Studiesnon-nucleoside reverse transcriptase inhibitorHuman immunodeficiency virusResearchMedical PharmacologyMiddle AgedTriazolesHealthy VolunteersArea Under CurveReverse Transcriptase InhibitorsFemaleRifampin

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being